Ronan Roussel1, Ray El Boustany1, Nadine Bouby1, Louis Potier1, Frédéric Fumeron1, Kamel Mohammedi1, Beverley Balkau1, Jean Tichet1, Lise Bankir1, Michel Marre1, Gilberto Velho1. 1. INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France.
Abstract
CONTEXT: Experimental data support a role for vasopressin in metabolic disorders. OBJECTIVE: We investigated associations of plasma copeptin, a surrogate of vasopressin, and of allelic variations in the arginine vasopressin-neurophysin II gene with insulin secretion, insulin sensitivity, and the risk for impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM). DESIGN, SETTING, AND PARTICIPANTS: We studied 5110 unrelated French men and women from a prospective cohort of the general population (Data from Epidemiological Study on the Insulin Resistance Syndrome cohort, 9-y follow-up). Six single nucleotide polymorphisms were genotyped. MAIN OUTCOME MEASURE: Incidence of IFG or T2DM during follow-up. RESULTS: The incidence of hyperglycemia (IFG/T2DM) during follow-up by quartiles of baseline plasma copeptin was 11.0% (Q1), 14.5% (Q2), 17.0% (Q3), and 23.5% (Q4), log-rank test P = .003. Participants in the upper quartile of plasma copeptin had significantly lower insulin sensitivity (homeostasis model assessment index) at baseline and during follow-up, as compared with other participants. Cox proportional hazards regression analyses showed significant associations of the CC genotype of rs6084264, the TT genotype of rs2282018, the C-allele of rs2770381, and the CC genotype of rs1410713 with the incidence of hyperglycemia. The genotypes associated with an increased risk of hyperglycemia were also associated with increased plasma copeptin in men but not in women. CONCLUSIONS: High plasma copeptin was associated with reduced insulin sensitivity and an increased risk for IFG/T2DM diabetes in this community-based cohort. Moreover, in men, allelic associations support a causal role for vasopressin in these disorders.
CONTEXT: Experimental data support a role for vasopressin in metabolic disorders. OBJECTIVE: We investigated associations of plasma copeptin, a surrogate of vasopressin, and of allelic variations in the arginine vasopressin-neurophysin II gene with insulin secretion, insulin sensitivity, and the risk for impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM). DESIGN, SETTING, AND PARTICIPANTS: We studied 5110 unrelated French men and women from a prospective cohort of the general population (Data from Epidemiological Study on the Insulin Resistance Syndrome cohort, 9-y follow-up). Six single nucleotide polymorphisms were genotyped. MAIN OUTCOME MEASURE: Incidence of IFG or T2DM during follow-up. RESULTS: The incidence of hyperglycemia (IFG/T2DM) during follow-up by quartiles of baseline plasma copeptin was 11.0% (Q1), 14.5% (Q2), 17.0% (Q3), and 23.5% (Q4), log-rank test P = .003. Participants in the upper quartile of plasma copeptin had significantly lower insulin sensitivity (homeostasis model assessment index) at baseline and during follow-up, as compared with other participants. Cox proportional hazards regression analyses showed significant associations of the CC genotype of rs6084264, the TT genotype of rs2282018, the C-allele of rs2770381, and the CC genotype of rs1410713 with the incidence of hyperglycemia. The genotypes associated with an increased risk of hyperglycemia were also associated with increased plasma copeptin in men but not in women. CONCLUSIONS: High plasma copeptin was associated with reduced insulin sensitivity and an increased risk for IFG/T2DM diabetes in this community-based cohort. Moreover, in men, allelic associations support a causal role for vasopressin in these disorders.
Authors: Sandrina Balanescu; Peter Kopp; Mary Beth Gaskill; Nils G Morgenthaler; Christian Schindler; Jonas Rutishauser Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958
Authors: Sofia Enhörning; Joachim Struck; Elisabet Wirfält; Bo Hedblad; Nils G Morgenthaler; Olle Melander Journal: J Clin Endocrinol Metab Date: 2011-04-13 Impact factor: 5.958
Authors: Umer Saleem; Mahyar Khaleghi; Nils G Morgenthaler; Andreas Bergmann; Joachim Struck; Thomas H Mosley; Iftikhar J Kullo Journal: J Clin Endocrinol Metab Date: 2009-04-14 Impact factor: 5.958
Authors: Sanjay S Bhandari; Ian Loke; Joan E Davies; Ian B Squire; Joachim Struck; Leong L Ng Journal: Clin Sci (Lond) Date: 2009-02 Impact factor: 6.124
Authors: Ray El Boustany; Irina Tasevska; Esther Meijer; Lyanne M Kieneker; Sofia Enhörning; Guillaume Lefèvre; Kamel Mohammedi; Michel Marre; Frédéric Fumeron; Beverley Balkau; Nadine Bouby; Lise Bankir; Stephan Jl Bakker; Ronan Roussel; Olle Melander; Ron T Gansevoort; Gilberto Velho Journal: JCI Insight Date: 2018-07-12
Authors: S Canivell; M Mohaupt; D Ackermann; M Pruijm; I Guessous; G Ehret; G Escher; A Pechère-Bertschi; B Vogt; O Devuyst; M Burnier; P-Y Martin; B Ponte; M Bochud Journal: J Endocrinol Invest Date: 2017-12-12 Impact factor: 4.256
Authors: Giovanna Muscogiuri; Luigi Barrea; Giuseppe Annunziata; Martina Vecchiarini; Francesco Orio; Carolina Di Somma; Annamaria Colao; Silvia Savastano Journal: Endocrine Date: 2018-07-19 Impact factor: 3.633
Authors: Y Lytvyn; P Bjornstad; A Katz; S K Singh; L C Godoy; L T Chung; C L Vinovskis; L Pyle; R Roussel; B A Perkins; D Cherney Journal: Diabetes Metab Date: 2019-12-06 Impact factor: 6.041
Authors: Petter Bjornstad; Richard J Johnson; Janet K Snell-Bergeon; Laura Pyle; Asa Davis; Nicole Foster; David Z Cherney; David M Maahs Journal: J Diabetes Complications Date: 2016-12-07 Impact factor: 2.852
Authors: M Vintilă; M L Gheorghiu; A Caragheorgheopol; N Baculescu; C Lichiardopol; C Badiu; M Coculescu; F Grigorescu; C Poiană Journal: J Med Life Date: 2016 Oct-Dec
Authors: Katarzyna Czarzasta; Agnieszka Cudnoch-Jedrzejewska; Longin Niemczyk; Robert Wrzesien; Marzanna Tkaczyk; Liana Puchalska; Marek Saracyn; Wawrzyniec Zmudzki; Stanisław Niemczyk Journal: Biomed Res Int Date: 2018-06-14 Impact factor: 3.411